178 related articles for article (PubMed ID: 11230491)
41. Effect of age on survival benefit of adjuvant chemotherapy in elderly patients with Stage III colon cancer.
Zuckerman IH; Rapp T; Onukwugha E; Davidoff A; Choti MA; Gardner J; Seal B; Mullins CD
J Am Geriatr Soc; 2009 Aug; 57(8):1403-10. PubMed ID: 19563521
[TBL] [Abstract][Full Text] [Related]
42. Comparison of SEER Treatment Data With Medicare Claims.
Noone AM; Lund JL; Mariotto A; Cronin K; McNeel T; Deapen D; Warren JL
Med Care; 2016 Sep; 54(9):e55-64. PubMed ID: 24638121
[TBL] [Abstract][Full Text] [Related]
43. Comparison of Medicare Claims-based Proxy Measures of Poor Function and Associations With Treatment Receipt and Mortality in Older Colon Cancer Patients.
Mayer SE; Tan HJ; Peacock Hinton S; Sanoff HK; Stürmer T; Hester LL; Faurot KR; Jonsson Funk M; Lund JL
Med Care; 2019 Apr; 57(4):286-294. PubMed ID: 30789540
[TBL] [Abstract][Full Text] [Related]
44. Strategies for improving comorbidity measures based on Medicare and Medicaid claims data.
Wang PS; Walker A; Tsuang M; Orav EJ; Levin R; Avorn J
J Clin Epidemiol; 2000 Jun; 53(6):571-8. PubMed ID: 10880775
[TBL] [Abstract][Full Text] [Related]
45. Evaluating the association between adjuvant chemotherapy and function-related adverse events among older patients with early stage breast cancer.
Mariano C; Lund JL; Peacock Hinton S; Htoo P; Muss H; Reeder-Hayes KE
J Geriatr Oncol; 2017 Jul; 8(4):242-248. PubMed ID: 28601373
[TBL] [Abstract][Full Text] [Related]
46. Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data.
Stokes ME; Thompson D; Montoya EL; Weinstein MC; Winer EP; Earle CC
Value Health; 2008; 11(2):213-20. PubMed ID: 18380633
[TBL] [Abstract][Full Text] [Related]
47. External validation of medicare claims for breast cancer chemotherapy compared with medical chart reviews.
Du XL; Key CR; Dickie L; Darling R; Geraci JM; Zhang D
Med Care; 2006 Feb; 44(2):124-31. PubMed ID: 16434911
[TBL] [Abstract][Full Text] [Related]
48. Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women.
Hershman DL; Wang X; McBride R; Jacobson JS; Grann VR; Neugut AI
Breast Cancer Res Treat; 2006 Oct; 99(3):313-21. PubMed ID: 16583264
[TBL] [Abstract][Full Text] [Related]
49. Data sources for measuring comorbidity: a comparison of hospital records and medicare claims for cancer patients.
Klabunde CN; Harlan LC; Warren JL
Med Care; 2006 Oct; 44(10):921-8. PubMed ID: 17001263
[TBL] [Abstract][Full Text] [Related]
50. Geographic variation and sociodemographic disparity in the use of oxaliplatin-containing chemotherapy in patients with stage III colon cancer.
Panchal JM; Lairson DR; Chan W; Du XL
Clin Colorectal Cancer; 2013 Jun; 12(2):113-21. PubMed ID: 23137529
[TBL] [Abstract][Full Text] [Related]
51. Predictors of timing of adjuvant chemotherapy in older women with hormone receptor-negative, stages II-III breast cancer.
Wheeler SB; Carpenter WR; Peppercorn J; Schenck AP; Weinberger M; Biddle AK
Breast Cancer Res Treat; 2012 Jan; 131(1):207-16. PubMed ID: 21842244
[TBL] [Abstract][Full Text] [Related]
52. Cost impact of oral capecitabine compared to intravenous taxane-based chemotherapy in first-line metastatic breast cancer.
Camacho FT; Wu J; Wei W; Kimmick G; Anderson RT; Balkrishnan R
J Med Econ; 2009 Sep; 12(3):238-45. PubMed ID: 19732030
[TBL] [Abstract][Full Text] [Related]
53. A SEER-Medicare population-based study of lymphedema-related claims incidence following breast cancer in men.
Reiner AS; Jacks LM; Van Zee KJ; Panageas KS
Breast Cancer Res Treat; 2011 Nov; 130(1):301-6. PubMed ID: 21735047
[TBL] [Abstract][Full Text] [Related]
54. Increase of chemotherapy use in older women with breast carcinoma from 1991 to 1996.
Du X; Goodwin JS
Cancer; 2001 Aug; 92(4):730-7. PubMed ID: 11550141
[TBL] [Abstract][Full Text] [Related]
55. The utility of Medicare claims data for measuring cancer stage.
Cooper GS; Yuan Z; Stange KC; Amini SB; Dennis LK; Rimm AA
Med Care; 1999 Jul; 37(7):706-11. PubMed ID: 10424641
[TBL] [Abstract][Full Text] [Related]
56. Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants.
Lamont EB; Herndon JE; Weeks JC; Henderson IC; Lilenbaum R; Schilsky RL; Christakis NA;
Med Care; 2008 Mar; 46(3):303-8. PubMed ID: 18388845
[TBL] [Abstract][Full Text] [Related]
57. Identifying specific chemotherapeutic agents in Medicare data: a validation study.
Lund JL; Stürmer T; Harlan LC; Sanoff HK; Sandler RS; Brookhart MA; Warren JL
Med Care; 2013 May; 51(5):e27-34. PubMed ID: 22080337
[TBL] [Abstract][Full Text] [Related]
58. Hospital-based health care use correlates with incidence of adverse events among elderly Medicare patients treated in adjuvant chemotherapy trials (Alliance 70802).
Lamont EB; Yu M; He Y; Saltz L; Muss H; Zaslavsky AM;
J Geriatr Oncol; 2014 Jul; 5(3):230-7. PubMed ID: 24594119
[TBL] [Abstract][Full Text] [Related]
59. Sensitivity of Medicare claims data for measuring use of standard multiagent chemotherapy regimens.
Lamont EB; Lan L
Med Care; 2014 Mar; 52(3):e15-20. PubMed ID: 22410411
[TBL] [Abstract][Full Text] [Related]
60. Complications associated with erythropoietin-stimulating agents in patients with metastatic breast cancer: a Surveillance, Epidemiology, and End Results-Medicare study.
Chavez-MacGregor M; Zhao H; Fang S; Srokowski TP; Hortobagyi GN; Giordano SH
Cancer; 2011 Aug; 117(16):3641-9. PubMed ID: 21656514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
